Biogen (NASDAQ:BIIB) Announces Quarterly Earnings Results

Biogen (NASDAQ:BIIB) released its quarterly earnings data on Wednesday. The biotechnology company reported $2.62 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.63, FiscalAI reports. The firm had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.63 billion. Biogen had a net margin of 3.37% and a return on equity of 9.38%. The business’s revenue was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $4.81 earnings per share.

Here are the key takeaways from Biogen’s conference call:

• Q3 revenue grew 11% year over year to $2.8 billion, driven by the growth portfolio and the first full quarter of SYFOVRE and EMPAVELI following the Apellis acquisition. Biogen raised the low end of its 2026 non-GAAP EPS outlook to $12.20–$13.00.
• The Apellis integration is progressing faster than expected, with the transaction now roughly operating-income neutral and at least $250 million in run-rate synergies targeted by the end of 2027. Biogen also expects the deal to be accretive to non-GAAP EPS in 2027.
• Biogen reported strong momentum across key growth products, including high-dose SPINRAZA, LEQEMBI, SKYCLARYS, SYFOVRE and EMPAVELI. The company said its growth portfolio represented approximately 63% of core pharmaceutical revenue and expects to return to overall top-line growth in 2026.
• The company highlighted a series of potentially important clinical catalysts, beginning with phase III SLE data for litifilimab in December and followed by readouts in cutaneous lupus, AMR and Dravet syndrome. Biogen also reported five INDs in 2026 and plans to build an early-stage pipeline of at least 20 programs over the next several years.
• Several reported Q3 sales benefited from temporary factors, including SPINRAZA conversion doses and inventory builds for SKYCLARYS and SYFOVRE, which are expected to reverse in Q4; contract manufacturing revenue is also expected to decline. VUMERITY revenue fell 11% year over year due to tighter Part D formulary management, while the upcoming pipeline readouts remain subject to clinical and regulatory risk.

Biogen Stock Up 2.3%

BIIB opened at $249.65 on Friday. Biogen has a fifty-two week low of $138.00 and a fifty-two week high of $258.78. The firm has a market capitalization of $36.89 billion, a P/E ratio of 106.69, a PEG ratio of 2.87 and a beta of 0.09. The company’s 50-day moving average is $226.29 and its 200 day moving average is $200.70. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.95 and a quick ratio of 1.26.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Canaccord Genuity Group upped their target price on shares of Biogen from $248.00 to $272.00 and gave the stock a “buy” rating in a report on Thursday. Citigroup reiterated a “neutral” rating on shares of Biogen in a research note on Wednesday. Argus raised Biogen from a “hold” rating to a “buy” rating and set a $280.00 price objective for the company in a report on Thursday. Seaport Research Partners raised Biogen to an “outperform” rating in a research note on Monday, October 12th. Finally, Wedbush increased their price objective on Biogen from $212.00 to $225.00 and gave the stock a “neutral” rating in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Biogen has an average rating of “Moderate Buy” and a consensus target price of $251.00.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q3 earnings beat expectations: Biogen reported adjusted EPS of $2.62 versus consensus of roughly $2.00 and revenue of $2.80 billion, up 10.6% year over year and ahead of estimates. Growth products, including newer rare-disease treatments and acquired assets, helped offset continued pressure on older multiple-sclerosis drugs. What Biogen Doubters Overlooked
• Positive Sentiment: Analyst sentiment improved materially: Needham and Baird raised their targets to $290, UBS increased its target to $300 while maintaining a buy rating, and RBC raised its target to $272 with an outperform rating. Argus also upgraded Biogen from hold to buy with a $280 target. Analysts Increase Their Forecasts on Biogen
• Positive Sentiment: Growth narrative is strengthening: RBC said Biogen has returned to growth, while management raised the low end of its 2026 earnings outlook. The company’s growth portfolio reportedly rose 49% and now represents 63% of core pharmaceutical sales, supporting the view that newer products can replace declining legacy revenue. Biogen Swings Back to Growth
• Positive Sentiment: Alzheimer’s pipeline remains a potential catalyst: Biogen plans to present long-term and real-world data for its Alzheimer’s portfolio at the November CTAD conference, including data on lecanemab and investigational diranersen. Biogen CTAD 2026 Data Announcement
• Neutral Sentiment: Analyst views are not unanimous: Truist and TD Cowen remain bullish, but Morgan Stanley kept an equal-weight rating with a $238 target, below the current trading level. Barclays also maintained equal weight despite lifting its target to $230. Biogen Analyst Target Updates
• Negative Sentiment: Risks remain: Biogen swung to a quarterly loss because of transaction-related charges, while higher costs led management to tighten its full-year adjusted EPS outlook. Unusually heavy put-option activity also signals that some traders remain defensive.

Biogen Company Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.